CoChat
Sign Up
Cited by 10Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic DiseasesCardiovascular Disease and Adiposity

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Severity of adipose tissue dysfunction is associated with progression of pre-diabetes to type 2 diabetes: the Tehran Lipid and Glucose Study

Open access
Jalali, Mohammad, Bahadoran, Zahra, Mirmiran, Parvin, Azizi, Fereidoun, Hosseinpanah, Farhad·2024·BMC Public Health
DOI 10.1186/s12889-023-17381-1PMC PMC10775602
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: The association of prediabetes (Pre-DM) regression and progression with visceral adiposity index (VAI) and adipose tissue dysfunction (ATD) remains to be investigated. Methods: The present cohort study was conducted within the framework of the Tehran Lipid and Glucose Study (TLGS) on 1458 Pre-DM cases (aged ≥ 21 years) who were followed for nine years. VAI was estimated based on waist circumference, body mass index, triglycerides, and high-density lipoprotein cholesterol. ATD status (i.e., absent, mild-moderate, and severe) was defined based on the age-stratified cutoff values of VAI. Multinomial logistic regression models with adjustment of potential confounders were used to estimate the chance of Pre-DM regression to normoglycemia or progression to T2D across ATD status. Results: During the study follow-up, 39.0% of the participants developed T2D, and 37.7% returned to normoglycemia. Compared to mild-moderate ATD, Pre-DM subjects with severe ATD had a higher risk of developing T2D by 45% (OR = 1.45, 95% CI = 11.08–1.93). Severe ATD was also associated with a decreased chance of returning to normoglycemia by 26% (OR = 0.74, 95% CI = 0.55–0.99). Participants with severe ATD had significantly higher fasting (overall mean = 111, 95% CI = 109–112 vs. 106, 95% CI = 105–108 mg/dL) and 2h-serum glucose (overall mean = 165, 95% CI = 161–168 vs. 153, 95% CI = 149–156 mg/dL) concentrations over time. Conclusion: Severe ATD was associated with an elevated risk of developing T2D and longitudinal poor-glycemic controls in Pre-DM subjects. ATD may be a simple and useful index for detecting subjects at a higher risk of Pre-DM progression to T2D, allowing for timely intervention strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12889-023-17381-1

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 60

  1. Rooney MR, Fang M, Ogurtsova K, Ozkan B, Echouffo-Tcheugui JB, Boyko EJ, Magliano DJ, Selvin EJDC. Global prevalence of prediabetes. Diabetes Care. 2023. https://doi.org/10.2337/dc22-2376:dc222376.10.2337/dc22-2376. · DOI
  2. DeJesus RS, Breitkopf CR, Rutten LJ, Jacobson DJ, Wilson PM, Sauver JS. Incidence rate of prediabetes progression to diabetes: modeling an optimum target group for intervention. Popul Health Manag. 2017;20(3):216–23. https://doi.org/10.1089/pop.2016.0067. · DOI
  3. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet (London, England). 2012;379(9833):2279–90. https://doi.org/10.1016/s0140-6736(12)60283-9. · DOI · Paper page
  4. Modi A, Gadhavi R, Pérez CM, Joshipura K. Longitudinal association between adiposity measures and regression of prediabetes/diabetes. Nutr Metab Cardiovasc Dis. 2021;31(11):3085–94. https://doi.org/10.1016/j.numecd.2021.07.005. · DOI
  5. Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308(11):1150–9. https://doi.org/10.1001/2012.jama.11132. · DOI
  6. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920–2. https://doi.org/10.2337/dc09-1825. · DOI · Paper page
  7. Zhou C, Zhang Y, Yang S, He P, Wu Q, Ye Z, Liu M, Zhang Y, Li R, Liu C, et al. Associations between visceral adiposity index and incident nephropathy outcomes in diabetic patients: Insights from the ACCORD trial. Diabetes Metab Res Rev. 2023;39(3): e3602. https://doi.org/10.1002/dmrr.3602. · DOI
  8. Zhou C, Zhang Z, Liu M, Zhang Y, He P, Li Q, Xie D, Liang M, Wang G, Nie J. Association of visceral adiposity index with new-onset type 2 diabetes and impaired fasting glucose in hypertensive Chinese adults. Eat Weight Disord-Stud Anorexia, Bulimia Obes. 2022;27:505. https://doi.org/10.1007/s40519-021-01187-4:1-10.10.1007/s40519-021-01187-4. · DOI
  9. Mousapour P, Barzin M, Valizadeh M, Mahdavi M, Azizi F, Hosseinpanah F. Predictive performance of lipid accumulation product and visceral adiposity index for renal function decline in non-diabetic adults, an 8.6-year follow-up. Clin Experiment Nephrol. 2020;24(3):225–34. https://doi.org/10.1007/s10157-019-01813-7. · DOI
  10. Amato MC, Giordano C. Visceral adiposity index: an indicator of adipose tissue dysfunction. Int J Endocrinol. 2014;2014:730827. https://doi.org/10.1155/2014/730827. · DOI
  11. Bozorgmanesh M, Hadaegh F, Azizi F. Predictive performance of the visceral adiposity index for a visceral adiposity-related risk: type 2 diabetes. Lipids Health Dis. 2011;10:88. https://doi.org/10.1186/1476-511x-10-88. · DOI
  12. Bagheri A, Khosravy T, Moradinazar M, Nachvak SM, Pasdar Y, Soleimani D, Samadi M. Optimal cut-off points of fat mass index and visceral adiposity index associated with type 2 diabetes mellitus. Food Sci Nutr. 2022;10(8):2710–7. https://doi.org/10.1002/fsn3.2874. · DOI
  13. Chen C, Xu Y, Guo ZR, Yang J, Wu M, Hu XS. The application of visceral adiposity index in identifying type 2 diabetes risks based on a prospective cohort in China. Lipids Health Dis. 2014;13:108. https://doi.org/10.1186/1476-511x-13-108. · DOI
  14. Bahadoran Z, Mirmiran P, Shabani M, Azizi F. Higher daily physical activity levels may facilitate pre-diabetes regression to normoglycemia: a longitudinal study among an Iranian population. Prev Med Rep. 2023;34:102233. https://doi.org/10.1016/j.pmedr.2023.102233. · DOI
  15. Azizi F, Zadeh-Vakili A, Takyar M. Review of rationale, design, and initial findings: Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2018;16(4 Suppl):e84777. https://doi.org/10.5812/ijem.84777. · DOI
  16. Naseri P, Amiri P, Masihay-Akbar H, Jalali-Farahani S, Khalili D, Azizi F. Long-term incidence of cardiovascular outcomes in the middle-aged and elderly with different patterns of physical activity: Tehran Lipid and Glucose Study. BMC Public Health. 2020;20(1):1–10. https://doi.org/10.1186/s12889-020-09747-6. · DOI
  17. Sheikholeslami S, Ghanbarian A, Azizi F. The impact of physical activity on non-communicable diseases: findings from 20 years of the Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2018;16(4 Suppl):e84740. https://doi.org/10.5812/ijem.84740. · DOI
  18. Askari S, Asghari G, Ghanbarian A, Khazan M, Alamdari S, Azizi F. Seasonal variations of blood pressure in adults: Tehran Lipid and Glucose Study. Arch Iranian Med. 2014;17(6):441–3 014176/aim.0012.
  19. Momenan AA, Delshad M, Sarbazi N, Rezaei Ghaleh N, Ghanbarian A, Azizi F. Reliability and validity of the Modifiable Activity Questionnaire (MAQ) in an Iranian urban adult population. Arch Iran Med. 2012;15(5):279–82. https://doi.org/10.4103/2008-7802.151433. · DOI
  20. Tohidi M, Ghasemi A, Hadaegh F, Derakhshan A, Chary A, Azizi F. Age- and sex-specific reference values for fasting serum insulin levels and insulin resistance/sensitivity indices in healthy Iranian adults: Tehran Lipid and Glucose Study. Clin Biochem. 2014;47(6):432–8. https://doi.org/10.1016/j.clinbiochem.2014.02.007. · DOI
  21. American Diabetes A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes care. 2021;44(Suppl 1):S15–33. https://doi.org/10.2337/dc21-S002. · DOI · Paper page
  22. Alizadeh Z, Baradaran HR, Kohansal K, Hadaegh F, Azizi F, Khalili D. Are the determinants of the progression to type 2 diabetes and regression to normoglycemia in the populations with pre-diabetes the same? Front Endocrinol. 2022;13:1041808. https://doi.org/10.3389/fendo.2022.1041808. · DOI
  23. Hosmer DW, Lemeshow S, Cook E: Applied logistic regression 2nd edition, https://doi.org/10.1002/9781118548387: John Wiley & Sons, Inc.; 2013. · DOI · Paper page
  24. Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690–1. https://doi.org/10.1001/jama.280.19.1690. · DOI · Paper page
  25. Faerch K, Borch-Johnsen K, Holst JJ, Vaag A. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia. 2009;52(9):1714–23. https://doi.org/10.1007/s00125-009-1443-3. · DOI
  26. Yang X, Smith U. Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia. 2007;50(6):1127–39. https://doi.org/10.1007/s00125-007-0640-1. · DOI
  27. Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care. 2000;23(8):1067–71. https://doi.org/10.2337/diacare.23.8.1067. · DOI
  28. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 1999;22(6):908–12. https://doi.org/10.2337/diacare.22.6.908. · DOI · Paper page
  29. Kim EH, Kim HK, Lee MJ, Bae SJ, Choe J, Jung CH, Kim CH, Park JY, Lee WJ. Sex differences of visceral fat area and visceral-to-subcutaneous fat ratio for the risk of incident type 2 diabetes mellitus. Diabetes Metab J. 2022;46(3):486–98. https://doi.org/10.4093/dmj.2021.0095. · DOI
  30. Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Ectopic fat obesity presents the greatest risk for incident type 2 diabetes: a population-based longitudinal study. Int J Obes (2005). 2019;43(1):139–48. https://doi.org/10.1038/s41366-018-0076-3. · DOI
  31. Yamazaki H, Tauchi S, Machann J, Haueise T, Yamamoto Y, Dohke M, Hanawa N, Kodama Y, Katanuma A, Stefan N, et al. Fat distribution patterns and future type 2 diabetes. Diabetes. 2022;71(9):1937–45. https://doi.org/10.2337/db22-0315. · DOI
  32. Heilbronn L, Smith SR, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes. 2004;28(4):S12–21. https://doi.org/10.1038/sj.ijo.0802853. · DOI
  33. Appari M, Channon KM, McNeill E. Metabolic regulation of adipose tissue macrophage function in obesity and diabetes. Antioxid Redox Signal. 2018;29(3):297–312. https://doi.org/10.1089/ars.2017.7060. · DOI
  34. Sung HK, Doh KO, Son JE, Park JG, Bae Y, Choi S, Nelson SML, Cowling R, Nagy K, Iacovos MP, et al. Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. Cell Metab. 2013;17(1):61–72. https://doi.org/10.1016/j.cmet.2012.12.010. · DOI
  35. Spencer M, Unal R, Zhu B, Rasouli N, McGehee RE Jr, Peterson CA, Kern PA. Adipose tissue extracellular matrix and vascular abnormalities in obesity and insulin resistance. J Clin Endocrinol Metab. 2011;96(12):E1990-1998. https://doi.org/10.1210/jc.2011-1567. · DOI
  36. Pasarica M, Gowronska-Kozak B, Burk D, Remedios I, Hymel D, Gimble J, Ravussin E, Bray GA, Smith SR. Adipose tissue collagen VI in obesity. J Clin Endocrinol Metab. 2009;94(12):5155–62. https://doi.org/10.1210/jc.2009-0947. · DOI
  37. Spencer M, Yao-Borengasser A, Unal R, Rasouli N, Gurley CM, Zhu B, Peterson CA, Kern PA. Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab. 2010;299(6):E1016-1027. https://doi.org/10.1152/ajpendo.00329.2010. · DOI · Paper page
  38. Rasouli N. Adipose tissue hypoxia and insulin resistance. J Investig Med. 2016;64(4):830–2. https://doi.org/10.1136/jim-2016-000106. · DOI
  39. Mazzatti D, Lim F-L, O’Hara A, Wood IS, Trayhurn P. A microarray analysis of the hypoxia-induced modulation of gene expression in human adipocytes. Arch Physiol Biochem. 2012;118(3):112–20. · DOI
  40. Lee MW, Lee M, Oh KJ. Adipose tissue-derived signatures for obesity and type 2 diabetes: Adipokines, Batokines and MicroRNAs. J Clin Med. 2019;8(6):854. https://doi.org/10.3390/jcm8060854. · DOI
  41. Koh EH, Park JY, Park HS, Jeon MJ, Ryu JW, Kim M, Kim SY, Kim MS, Kim SW, Park IS, et al. Essential role of mitochondrial function in adiponectin synthesis in adipocytes. Diabetes. 2007;56(12):2973–81. https://doi.org/10.2337/db07-0510. · DOI · Paper page
  42. Guglielmi V, Cardellini M, Cinti F, Corgosinho F, Cardolini I, D’Adamo M, Zingaretti MC, Bellia A, Lauro D, Gentileschi P, et al. Omental adipose tissue fibrosis and insulin resistance in severe obesity. Nutr Diabetes. 2015;5(8):e175–e175. https://doi.org/10.1038/nutd.2015.22. · DOI
  43. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(5):367–77. https://doi.org/10.1038/nrm2391. · DOI · Paper page
  44. Colleluori G, Perugini J. From obesity to diabetes: the role of the adipose organ. Handb Exp Pharmacol. 2022;274:75–92. https://doi.org/10.1007/164_2021_572. · DOI
  45. Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother. 2021;137:111315. https://doi.org/10.1016/j.biopha.2021.111315. · DOI
  46. Santoro A, Kahn BB. Adipocyte regulation of insulin sensitivity and the risk of type 2 diabetes. N Engl J Med. 2023;388(22):2071–85. · DOI
  47. Koloverou E, Panagiotakos DB, Kyrou I, Stefanadis C, Chrysohoou C, Georgousopoulou EN, Skoumas I, Tousoulis D, Pitsavos C. group tAS: Visceral adiposity index outperforms common anthropometric indices in predicting 10-year diabetes risk: results from the ATTICA study. Diabetes Metab Res Rev. 2019;35(6): e3161. https://doi.org/10.1002/dmrr.3161. · DOI
  48. Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HFJD. Tumor necrosis factor-α suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-κB activation by TNF-α is obligatory. Diabetes. 2002;51(5):1319–36. https://doi.org/10.2337/diabetes.51.5.1319. · DOI
  49. Qatanani M, Lazar MAJG. development: mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 2007;21(12):1443–55. https://doi.org/10.1101/gad.1550907. · DOI
  50. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007;87(2):507–20. https://doi.org/10.1152/physrev.00024.2006. · DOI · Paper page
  51. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β-cell dysfunction. Eur J Clin Invest. 2002;32:14–23. https://doi.org/10.1046/j.1365-2362.32.s3.3.x. · DOI · Paper page
  52. Bergmann K, Sypniewska G. Medicine L: Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers? Clin Chem Lab Med. 2013;51(1):177–85. https://doi.org/10.1515/cclm-2012-0490. · DOI
  53. Sonoli S, Shivprasad S, Prasad C, Patil A, Desai P, Somannavar MS. Visfatin-a review. Eur Rev Med Pharmacol Sci. 2011;15(1):9–14 PMID: 21381495.
  54. Heo YJ, Choi S-E, Jeon JY, Han SJ, Kim DJ, Kang Y, Lee KW, Kim HJ. Visfatin induces inflammation and insulin resistance via the NF-κB and STAT3 signaling pathways in hepatocytes. J Diabetes Res. 2019;2019:4021623. https://doi.org/10.1155/2019/4021623. · DOI
  55. Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, Charalampidis P, Livadas S, Kollias A, Sabico SL, Chrousos GP. Visceral adiposity index is highly associated with adiponectin values and glycaemic disturbances. Eur J Clin Invest. 2013;43(2):183–9. https://doi.org/10.1111/eci.12030. · DOI
  56. Ciresi A, Amato MC, Pizzolanti G, Giordano Galluzzo C. Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. J Clin Endocrinol Metab. 2012;97(8):2907–15. https://doi.org/10.1210/jc.2012-1518. · DOI
  57. Zhang M, Zheng L, Li P, Zhu Y, Chang H, Wang X, Liu W, Zhang Y, Huang G. 4-year trajectory of visceral adiposity index in the development of type 2 diabetes: a prospective cohort study. Ann Nutr Metab. 2016;69(2):142–9. https://doi.org/10.1159/000450657. · DOI
  58. Yang J, Wang F, Wang J, Han X, Hu H, Yu C, Yuan J, Yao P, Miao X, Wei S, et al. Using different anthropometric indices to assess prediction ability of type 2 diabetes in elderly population: a 5 year prospective study. BMC Geriatr. 2018;18(1):218. https://doi.org/10.1186/s12877-018-0912-2. · DOI
  59. Wang Y, He S, He J, Wang S, Liu K, Chen X. Predictive value of visceral adiposity index for type 2 diabetes mellitus: a 15-year prospective cohort study. Herz. 2015;40(Suppl 3):277–81. https://doi.org/10.1007/s00059-014-4175-1. · DOI
  60. Liu PJ, Ma F, Lou HP, Chen Y. Visceral adiposity index is associated with pre-diabetes and type 2 diabetes mellitus in Chinese adults aged 20–50. Ann Nutr Metab. 2016;68(4):235–43. https://doi.org/10.1159/000446121. · DOI

Cited by

Sorted by citations

Metadata

Authors
Jalali, M., Bahadoran, Z., Mirmiran, P., Azizi, F., & Hosseinpanah, F.
Affiliations
  • Shiraz University of Medical Sciences (IR)
  • Research Institute for Endocrine Sciences (IR)
Corresponding author
Bahadoran, Zahra
ORCID
Venue
BMC Public Health
Publisher
Springer Science and Business Media LLC
Published
2024-01-09
Volume
24
Issue
1
Pages
121-121
ISSN
1471-2458 (ISSN-L)
DOI
10.1186/s12889-023-17381-1
PMC
PMC10775602
OpenAlex
W4390744269
Cited by
10
References
5
Citations by year
2026: 2 · 2025: 5 · 2024: 3
FWCI
3.29
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Public Health (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Shahid Beheshti University of Medical Sciences
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords
adipose tissue dysfunction, prediabetes, type 2 diabetes progression, visceral adiposity index, glycemic control, fasting blood glucose, 2-hour plasma glucose, insulin resistance, Tehran Lipid and Glucose Study
MeSH terms
Adipose Tissue, Diabetes Mellitus, Type 2, Glucose, Humans, Iran, Cholesterol, HDL, Prediabetic State, Cohort Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review